Investors Alerted by Robbins LLP of Class Action Lawsuit Against RGNX Stock

Robbins LLP is informing investors about a class action lawsuit against REGENXBIO, Inc. The lawsuit is on behalf of investors who bought or acquired REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026. REGENXBIO is a company that deals with gene therapies for genetic defects in the United States.

The complaint alleges that defendants promoted RGX-111 as a leading AAV therapeutic product candidate for the treatment of MPS I. They claimed that the Phase I/II studies on RGX-111 showed positive safety and biomarker data. However, it was later revealed that there were serious safety concerns, including the potential for CNS neoplasm. In November 2023, the company decided to de-prioritize RGX-111 and explore other options for the program.

In January 2026, the FDA placed a clinical hold on RGX-111 due to safety concerns following the discovery of a neoplasm in a participant. This news caused a significant decline in REGENXBIO’s stock price. Shareholders who want to lead the class action lawsuit must submit their papers by April 14, 2026.

Robbins LLP is a well-known firm specializing in shareholder rights litigation. They have been dedicated to helping shareholders recover losses, enhance corporate governance, and hold company executives accountable since 2002. Shareholders involved in the case will not have to pay any fees or expenses as representation is on a contingency fee basis.

If you want to receive updates on the class action against REGENXBIO or stay informed about corporate executives involved in misconduct, you can sign up for Stock Watch. Please note that past results do not guarantee similar outcomes in legal proceedings. For more details on the lawsuit or to participate in the class action, contact Aaron Dumas, Jr. at Robbins LLP.